August 31, 2011 10-Q/A

0001078782-11-003119.txt : 20111102 0001078782-11-003119.hdr.sgml : 20111102 20111102135458 ACCESSION NUMBER: 0001078782-11-003119 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110831 FILED AS OF DATE: 20111102 DATE AS OF CHANGE: 20111102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMA INVESTING NEWS, INC. CENTRAL INDEX KEY: 0001520047 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 320337695 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 333-174271 FILM NUMBER: 111173942 BUSINESS ADDRESS: STREET 1: 833 SEYMOUR ST., UNIT 1008 CITY: VANCOUVER STATE: A1 ZIP: V5T 0A4 BUSINESS PHONE: 604-563-8467 MAIL ADDRESS: STREET 1: 833 SEYMOUR ST., UNIT 1008 CITY: VANCOUVER STATE: A1 ZIP: V5T 0A4 10-Q/A 1 f10qa083111_10qz.htm AUGUST 31, 2011 10-Q/A August 31, 2011 10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 10-Q/A

______________

X . QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended August 31, 2011

. TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

For the transition period from ______ to _______

Commission File Number 333-174271

PHARMA INVESTING NEWS, INC.

(Exact name of registrant as specified in its charter)


Nevada		32-0337695
(State of incorporation)		(I.R.S. Employer Identification No.)

833 Seymour St., Unit 1008

Vancouver, B.C.

Canada, V5T 0A4

(Address of principal executive offices)

Phone: (604) 563-8467

(Registrant’s telephone number)

with a copy to:

Carrillo Huettel, LLP

3033 Fifth Ave. Suite 400

San Diego, CA 92103

Telephone (619) 546-6100

Facsimile (619) 546-6060

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. X . Yes . No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). X . Yes . No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller Reporting Company

X .

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). . Yes X . No

As of October 26, 2011, there were 5,000,000 shares of the registrant’s $.001 par value Common Stock issued and outstanding.

EXPLANATORY NOTE

The purpose of this Amendment No. 1 to the Quarterly Report of Pharma Investing News, Inc. (the “Company”) on Form 10-Q/A for the quarterly period ended August 31, 2011, filed with the Securities and Exchange Commission on October 26, 2011 (the “Form 10-Q”), is to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).

Other than the aforementioned, no other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

ITEM 6.

EXHIBITS


Exhibit Number	Description of Exhibit	Filing
3.01	Articles of Incorporation	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
3.02	Bylaws	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
10.01	Promissory Note between the Company and Robert Lawrence Dated April 18, 2011	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
10.02	Joint Venture Agreement between the Company and Healthcare Media Dated July 22, 2011	Filed with the SEC on July 27, 2011 as part of our Amended Registration Statement on Form S-1/A.
10.03	Promissory Note between the Company and Robert Lawrence Dated August 25, 2011	Filed with the SEC on August 30, 2011 as part of our Amended Registration Statement on Form S-1/A.
10.04	Promissory Note between the Company and Robert Lawrence Dated August 26, 2011	Filed with the SEC on August 30, 2011 as part of our Amended Registration Statement on Form S-1/A.
14.01	Code of Ethics	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
31.01	Certification of Principal Executive Officer Pursuant to Rule 13a-14	Filed herewith.
31.02	Certification of Principal Financial Officer Pursuant to Rule 13a-14	Filed herewith.
32.01	CEO and CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith.
101.INS*	XBRL Instance Document	Filed herewith.
101.SCH*	XBRL Taxonomy Extension Schema Document	Filed herewith.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.
101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document	Filed herewith.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.

*Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



		PHARMA INVESTING NEWS, INC.
Dated: November 2, 2011		/s/ Robert Lawrence
		By: ROBERT LAWRENCE
		Its: President and CEO

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

Dated: November 2, 2011

/s/ Robert Lawrence

By: Robert Lawrence

Its: Director

EX-31.1 2 certification_ex31z1.htm EX 31.1 SECTION 302 CERTIFICATIONS EX 31.1 Section 302 Certifications

Exhibit 31.01

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Robert Lawrence, certify that:

I have reviewed this Amended Quarterly Report on Form 10-Q/A of Pharma Investing News, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 2, 2011

/s/ Robert Lawrence

By: Robert Lawrence

Its: Principal Executive Officer

EX-31.2 3 certification_ex31z2.htm EX 31.2 SECTION 302 CERTIFICATIONS EX 31.2 Section 302 Certifications

Exhibit 31.02

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14

I, Robert Lawrence, certify that:

I have reviewed this Amended Quarterly Report on Form 10-Q/A of Pharma Investing News, Inc.;

(b)

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 2, 2011

/s/ Robert Lawrence

By: Robert Lawrence

Its: Principal Financial Officer

EX-32.1 4 certification_ex32z1.htm EX 32.1 SECTION 906 CERTIFICATIONS EX 32.1 Section 906 Certifications

Exhibit 32.01

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Amended Quarterly Report of Pharma Investing News, Inc. (the “Company”) on Form 10-Q/A for the period ending August 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Lawrence, Chief Executive Officer and Chief Financial Officer, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Robert Lawrence

By: Robert Lawrence

Chief Executive Officer and Chief Financial Officer

Dated: November 2, 2011

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 pini-20110831.xml XBRL INSTANCE DOCUMENT 10-Q 2011-08-31 false PHARMA INVESTING NEWS, INC. 0001520047 --02-28 5000000 Smaller Reporting Company Yes No No 2012 Q2

4121

9000

4121

9000

17382

5000

31826

10000

49208

15000

5000

-5000

-45087

-6000

-45087

-6000

4121

9000

0.001

10000000

0.001

290000000

5000000

5000 5000 5000

1321

2503

3503

17792

31584

36584

24113

39087

45087

-24113

-39087

-45087

0.00

-0.01

5000000 5000000 0

-39087

-45087

12382

17382

-26705

-27705

21826

31826

21826

31826

-4879

4121

1. Nature of Operations and Continuance of Business   Pharma Investing News, Inc. (the Company) was incorporated in the State of Nevada on February 1, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915, Development Stage Entities.   Going Concern  These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of August 31, 2011, the Company has not recognized any revenue, and has an accumulated deficit of $45,087. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Companys future operations. These factors raise substantial doubt regarding the Companys ability to continue as a going concern.  These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern

2. Summary of Significant Accounting Policies   a) Basis of Presentation   The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) and are expressed in U.S. dollars.  The Companys fiscal year end is February 28.   b) Interim Financial Statements   These interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Companys audited financial statements and notes thereto for the period ended February 28, 2011.   The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Companys financial position at August 31, 2011, and the results of its operations and cash flows for the three and six month periods ended August 31, 2011. The results of operations for the period ended August 31, 2011 are not necessarily indicative of the results to be expected for future quarters or the full year.   c) Use of Estimates   The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.   d) Cash and cash equivalents   The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.   e) Basic and Diluted Net Loss per Share   The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive.   f) Financial Instruments   Pursuant to ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instruments categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:   Level 1   Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.   Level 2   Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.   Level 3   Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.   The Companys financial instruments consist principally of cash, and amounts due to related parties.  Pursuant to ASC 820, the fair value of our cash is determined based on Level 1 inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.   g) Comprehensive Loss   ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of August 31, 2011 and February 28, 2011, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.     h) Recent Accounting Pronouncements   In February 2010, the FASB issued ASU No. 2010-09 Subsequent Events (ASC Topic 855) Amendments to Certain Recognition and Disclosure Requirements (ASU No. 2010-09). ASU No. 2010-09 requires an entity that is an SEC filer to evaluate subsequent events through the date that the financial statements are issued and removes the requirement for an SEC filer to disclose a date, in both issued and revised financial statements, through which the filer had evaluated subsequent events. The adoption did not have an impact on the Companys financial position and results of operations.   The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations

3. Related Party Transactions  As at August 31, 2011, the Company owes $31,826 (February 28, 2011 - $10,000) to the President and CEO of the Company. The amount owing is unsecured, non-interest bearing, and due on demand

4. Subsequent Events   We have evaluated subsequent events through the date of issuance of the financial statements, and did not have any material recognizable subsequent events.

0001520047 2011-06-01 2011-08-31 0001520047 2011-10-26 0001520047 2011-08-31 0001520047 2011-02-28 0001520047 2011-03-01 2011-08-31 0001520047 2011-02-01 2011-08-31 0001520047 2011-01-31 iso4217:USD shares iso4217:USD shares EX-101.CAL 6 pini-20110831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 pini-20110831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 pini-20110831_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Supplemental Disclosures STOCKHOLDERS' DEFICIT Entity Voluntary Filers Net Cash Provided by Financing Activities Changes in operating assets and liabilities: Professional fees Total Liabilities and Stockholders' Deficit Due to related parties Entity Registrant Name Income tax paid Net Cash Used In Operating Activities General and administrative Operating Expenses {1} Operating Expenses Common stock, par or stated value ASSETS Document Period End Date Nature of Operations and Continuance of Business Increase (Decrease) in Cash Additional paid-in capital Current Fiscal Year End Date Amendment Flag Weighted Average Shares Outstanding - Basic and Diluted The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS. Revenues Entity Current Reporting Status Subsequent Events {1} Subsequent Events Summary of Significant Accounting Policies Financing Activities Total Liabilities Total Assets Cash {1} Cash Cash - Beginning of Period Cash - End of Period Entity Central Index Key Accounts payable {1} Accounts payable Operating Activities Total Operating Expenses Common stock, shares authorized Preferred Stock, shares authorized Statement [Line Items] Accumulated deficit during the development stage Net loss for the period Total Stockholders' Deficit Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,000,000 common shares Document Fiscal Year Focus Document and Entity Information Consulting fees The charge during the reporting period towards consultation charges Current Liabilities Proceeds from related party Net Loss per Share - Basic and Diluted Statement [Table] Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares Entity Filer Category Subsequent Events Nature of Operations and Continuance of Business {1} Nature of Operations and Continuance of Business StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract LIABILITIES Common Stock, shares issued Document Fiscal Period Focus Entity Common Stock, Shares Outstanding Net Loss Entity Well-known Seasoned Issuer Related Party Transactions Interest paid IncomeStatementAbstract Preferred Stock, par or stated value Related Party Transactions {1} Related Party Transactions Summary of Significant Accounting Policies {1} Summary of Significant Accounting Policies Document Type Common Stock, shares outstanding Accounts payable EX-101.PRE 9 pini-20110831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 pini-20110831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000030 - Statement - Balance Sheets Parentheticals link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Organization, Consolidation and Presentation of Financial Statements link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000061 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000062 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000063 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink XML 11 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets Parentheticals (USD $)	Aug. 31, 2011	Feb. 28, 2011
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Common stock, par or stated value	$ 0.001	$ 0.001
Common stock, shares authorized	290,000,000	290,000,000
Common Stock, shares issued	5,000,000	5,000,000
Common Stock, shares outstanding	5,000,000	5,000,000

XML 12 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (USD $)	3 Months Ended	6 Months Ended	7 Months Ended
Statements of Operations (USD $)	Aug. 31, 2011	Aug. 31, 2011	Aug. 31, 2011
IncomeStatementAbstract
Revenues	$ 0	$ 0	$ 0
Operating Expenses
Consulting fees	5,000	5,000	5,000
General and administrative	1,321	2,503	3,503
Professional fees	17,792	31,584	36,584
Total Operating Expenses	24,113	39,087	45,087
Net Loss	$ (24,113)	$ (39,087)	$ (45,087)
Net Loss per Share - Basic and Diluted	$ 0.00	$ (0.01)	$ 0
Weighted Average Shares Outstanding - Basic and Diluted	5,000,000	5,000,000	0

XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Aug. 31, 2011	Oct. 26, 2011
Document and Entity Information
Entity Registrant Name	PHARMA INVESTING NEWS, INC.
Document Type	10-Q
Document Period End Date	Aug. 31, 2011
Amendment Flag	false
Entity Central Index Key	0001520047
Current Fiscal Year End Date	--02-28
Entity Common Stock, Shares Outstanding		5,000,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2

XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 15 R8.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Aug. 31, 2011

Related Party Transactions

Related Party Transactions

3. Related Party Transactions

As at August 31, 2011, the Company owes $31,826 (February 28, 2011 - $10,000) to the President and CEO of the Company. The amount owing is unsecured, non-interest bearing, and due on demand

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Organization, Consolidation and Presentation of Financial Statements

3 Months Ended

Aug. 31, 2011

Nature of Operations and Continuance of Business

Nature of Operations and Continuance of Business

1. Nature of Operations and Continuance of Business

Pharma Investing News, Inc. (the “Company”) was incorporated in the State of Nevada on February 1, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915, Development Stage Entities.

Going Concern

These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of August 31, 2011, the Company has not recognized any revenue, and has an accumulated deficit of $45,087. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern

XML 17 R9.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Aug. 31, 2011

Subsequent Events

Subsequent Events

4. Subsequent Events

We have evaluated subsequent events through the date of issuance of the financial statements, and did not have any material recognizable subsequent events.

XML 18 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 19 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (USD $)	6 Months Ended	7 Months Ended
Statements of Cash Flows (USD $)	Aug. 31, 2011	Aug. 31, 2011
Operating Activities
Net loss for the period	$ (39,087)	$ (45,087)
Changes in operating assets and liabilities:
Accounts payable	12,382	17,382
Net Cash Used In Operating Activities	(26,705)	(27,705)
Financing Activities
Proceeds from related party	21,826	31,826
Net Cash Provided by Financing Activities	21,826	31,826
Increase (Decrease) in Cash	(4,879)	4,121
Cash - Beginning of Period	9,000	0
Cash - End of Period	4,121	4,121
Supplemental Disclosures
Interest paid	0	0
Income tax paid	$ 0	$ 0

XML 20 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Aug. 31, 2011

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

a) Basis of Presentation

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is February 28.

b) Interim Financial Statements

These interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the period ended February 28, 2011.

The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at August 31, 2011, and the results of its operations and cash flows for the three and six month periods ended August 31, 2011. The results of operations for the period ended August 31, 2011 are not necessarily indicative of the results to be expected for future quarters or the full year.

c) Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

d) Cash and cash equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

e) Basic and Diluted Net Loss per Share

The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive.

f) Financial Instruments

Pursuant to ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, and amounts due to related parties. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

g) Comprehensive Loss

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of August 31, 2011 and February 28, 2011, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

h) Recent Accounting Pronouncements

In February 2010, the FASB issued ASU No. 2010-09 “Subsequent Events (ASC Topic 855) “Amendments to Certain Recognition and Disclosure Requirements” (“ASU No. 2010-09”). ASU No. 2010-09 requires an entity that is an SEC filer to evaluate subsequent events through the date that the financial statements are issued and removes the requirement for an SEC filer to disclose a date, in both issued and revised financial statements, through which the filer had evaluated subsequent events. The adoption did not have an impact on the Company’s financial position and results of operations.

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations

XML 21 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (USD $)	Aug. 31, 2011	Feb. 28, 2011
ASSETS
Cash	$ 4,121	$ 9,000
Total Assets	4,121	9,000
LIABILITIES
Accounts payable	17,382	5,000
Due to related parties	31,826	10,000
Total Liabilities	49,208	15,000
STOCKHOLDERS' DEFICIT
Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares	0	0
Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,000,000 common shares	5,000	5,000
Additional paid-in capital	(5,000)	(5,000)
Accumulated deficit during the development stage	(45,087)	(6,000)
Total Stockholders' Deficit	(45,087)	(6,000)
Total Liabilities and Stockholders' Deficit	$ 4,121	$ 9,000

XML 22 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.15 Html 7 50 1 false 0 0 false 3 true false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.pharmainvestingnews.com/20110831/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information false false R2.htm 000020 - Statement - Balance Sheets Sheet http://www.pharmainvestingnews.com/20110831/role/idr_BalanceSheets Balance Sheets false false R3.htm 000030 - Statement - Balance Sheets Parentheticals Sheet http://www.pharmainvestingnews.com/20110831/role/idr_BalanceSheetsParentheticals Balance Sheets Parentheticals false false R4.htm 000040 - Statement - Statements of Operations Sheet http://www.pharmainvestingnews.com/20110831/role/idr_StatementsOfOperations Statements of Operations false false R5.htm 000050 - Statement - Statements of Cash Flows Sheet http://www.pharmainvestingnews.com/20110831/role/idr_StatementsOfCashFlows Statements of Cash Flows false false R6.htm 000060 - Disclosure - Organization, Consolidation and Presentation of Financial Statements Sheet http://www.pharmainvestingnews.com/20110831/role/idr_DisclosureOrganizationConsolidationAndPresentationOfFinancialStatements Organization, Consolidation and Presentation of Financial Statements false false R7.htm 000061 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pharmainvestingnews.com/20110831/role/idr_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R8.htm 000062 - Disclosure - Related Party Transactions Sheet http://www.pharmainvestingnews.com/20110831/role/idr_DisclosureRelatedPartyTransactions Related Party Transactions false false R9.htm 000063 - Disclosure - Subsequent Events Sheet http://www.pharmainvestingnews.com/20110831/role/idr_DisclosureSubsequentEvents Subsequent Events false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Balance Sheets Process Flow-Through: Removing column 'Jan. 31, 2011' Process Flow-Through: 000030 - Statement - Balance Sheets Parentheticals Process Flow-Through: 000040 - Statement - Statements of Operations Process Flow-Through: 000050 - Statement - Statements of Cash Flows pini-20110831.xml pini-20110831.xsd pini-20110831_cal.xml pini-20110831_def.xml pini-20110831_lab.xml pini-20110831_pre.xml true true EXCEL 23 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U8F)A9C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?3W!E#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]#;VYS;VQI9&%T:6]N7V%N9#PO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I3='EL97-H M965T($A2968],T0B5V]R:W-H965T3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U8F)A9C'0O:'1M;#L@ M8VAA2!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^075G(#,Q M+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^9F%L2!#96YT3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,34R,#`T-SQS<&%N M/CPO'0^+2TP,BTR.#QS<&%N/CPO2!&:6QE3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^3F\\2!796QL+6MN;W=N(%-E87-O;F5D($ES'0^3F\\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQAF5D.B`Q,"PP,#`L,#`P('!R969E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U8F)A9C'0O M:'1M;#L@8VAA'1087)T7S5B8F%F-SAF7S4Q9CA?-&(Q-%]A8S5B7V$V,64X,S@V-&)A M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U8F)A9C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$"!P86ED/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XF;F)S<#LD(#`\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA28C,30X.RD@=V%S M(&EN8V]R<&]R871E9"!I;B!T:&4@4W1A=&4@;V8@3F5V861A(&]N($9E8G)U M87)Y(#$L(#(P,3$N(%1H92!#;VUP86YY(&ES(&$@1&5V96QO<&UE;G0@4W1A M9V4@0V]M<&%N>2P@87,@9&5F:6YE9"!B>2!&:6YA;F-I86P@06-C;W5N=&EN M9R!3=&%N9&%R9',@0F]A6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O M;G0@;&%N9STS1$5.+4E./B9N8G-P.SPO9F]N=#X\+W`^/&9O;G0@;&%N9STS M1$5.+4E./E1H97-E(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!P M2!W:6QL(&-O;G1I;G5E('1O(')E86QI>F4@ M:71S(&%S2!H87,@;F]T(')E8V]G;FEZ960@86YY(')E M=F5N=64L(&%N9"!H87,@86X@86-C=6UU;&%T960@9&5F:6-I="!O9B`F;F)S M<#LD-#4L,#@W+B!4:&4@8V]N=&EN=6%T:6]N(&]F('1H92!#;VUP86YY(&%S M(&$@9V]I;F<@8V]N8V5R;B!I2!D96)T(&]R M(&5Q=6ET>2!F:6YA;F-I;F2!S:&]U;&0@=&AE M($-O;7!A;GD@8F4@=6YA8FQE('1O(&-O;G1I;G5E(&%S(&$@9V]I;F<@8V]N M8V5R;CPO9F]N=#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO2!O M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TU!4D=)3CHP M:6X@,&EN(#!P="<^/&(^/&9O;G0@;&%N9STS1$5.+4E./C(N(%-U;6UA6QE/3-$)TU! M4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@;&%N9STS1$5.+4E./B9N8G-P.SPO M9F]N=#X\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.C`N,C5I;CL@34%2 M1TE..C!I;B`P:6X@,'!T)SX\9F]N="!L86YG/3-$14XM24X^82D@0F%S:7,@ M;V8@4')E2!A8V-E<'1E9"!I;B!T M:&4@56YI=&5D(%-T871E'!R97-S960@:6X@52Y3+B!D;VQL87)S+B`F;F)S<#M4:&4@0V]M<&%N M>28C,30V.W,@9FES8V%L('EE87(@96YD(&ES($9E8G)U87)Y(#(X+CPO9F]N M=#X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@ M;&%N9STS1$5.+4E./B9N8G-P.SPO9F]N=#X\+W`^(#QP('-T>6QE/3-$)U1% M6%0M24Y$14Y4.C`N,C5I;CL@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!L M86YG/3-$14XM24X^8BD@26YT97)I;2!&:6YA;F-I86P@4W1A=&5M96YT6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O M;G0@;&%N9STS1$5.+4E./B9N8G-P.SPO9F]N=#X\+W`^(#QP('-T>6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@;&%N9STS1$5.+4E./E1H97-E M(&EN=&5R:6T@=6YA=61I=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@ M8F5E;B!P2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T M871E2!A8V-E<'1E9"!A8V-O=6YT M:6YG('!R:6YC:7!L97,@9F]R(&-O;7!L971E(&9I;F%N8VEA;"!S=&%T96UE M;G1S+B!4:&5R969O'!E8W1E9"!F;W(@9G5T=7)E('%U M87)T97)S(&]R('1H92!F=6QL('EE87(N/"]F;VYT/CPO<#X@/'`@28C,30V.W,@97-T:6UA=&5S+B!4;R!T:&4@97AT96YT('1H97)E M(&%R92!M871E6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@;&%N9STS1$5.+4E. M/B9N8G-P.SPO9F]N=#X\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.C`N M,C5I;CL@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!L86YG/3-$14XM24X^ M9"D@0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@;&%N9STS1$5.+4E. M/B9N8G-P.SPO9F]N=#X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN M(#!P="<^/&9O;G0@;&%N9STS1$5.+4E./E1H92!#;VUP86YY(&-O;G-I9&5R M&5R8VES92!O9B!S M=&]C:R!O<'1I;VYS(&]R('=A&-L=61E MF4@=&AE('5S92!O9B!U;F]B2!B87-E9"!O;B!T:&4@ M;&5V96P@;V8@:6YD97!E;F1E;G0L(&]B:F5C=&EV92!E=FED96YC92!S=7)R M;W5N9&EN9R!T:&4@:6YP=71S('5S960@=&\@;65AF5S('1H92!I;G!U=',@:6YT;R!T:')E92!L979E;',@=&AA="!M M87D@8F4@=7-E9"!T;R!M96%S=7)E(&9A:7(@=F%L=64Z/"]F;VYT/CPO<#X@ M/'`@2!S=6-H(&%S('%U;W1E9"!P2!F28C,30V M.W,@9FEN86YC:6%L(&EN2!O9B!C;VUP2`R."P@,C`Q,2P@=&AE($-O;7!A;GD@:&%S(&YO(&ET96US('1H870@ M6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@;&%N9STS1$5.+4E./B9N8G-P M.SPO9F]N=#X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^ M/&9O;G0@;&%N9STS1$5.+4E./DEN($9E8G)U87)Y(#(P,3`L('1H92!&05-" M(&ES7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!43X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\U8F)A9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)TU!4D=) M3CHP:6X@,&EN(#!P="<^/&9O;G0@;&%N9STS1$5.+4E./B9N8G-P.SPO9F]N M=#X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@ M;&%N9STS1$5.+4E./E=E(&AA=F4@979A;'5A=&5D('-U8G-E<75E;G0@979E M;G1S('1H2!M871EF%B;&4@ ZIP 24 0001078782-11-003119-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001078782-11-003119-xbrl.zip M4$L#!!0````(`.%N8C_NQ<,+714``'5X```1`!P`<&EN:2TR,#$Q,#@S,2YX M;6Q55`D``_6#L4[U@[%.=7@+``$$)0X```0Y`0``[3UK<^,VDI]S5?%QER9+\&'OLR9;']F1=21ROY4EV/UU!)"0A0Q$*0Y&H]]H4*=_?YA$;"82+57\?JO;[FPQ$0]VT3$C/"IRFL[)L=>[AK'F[!/G]UBHMY MIXEEMV+(B`_OTL>I>+^EY60:(=7TW3@1P_=;4QG+EMNZ]H,.M]@NP0%A>'>A M@FPBXO0.IK-`Q:EX2&]QU@6,/^QT_]?N^+?=3NN?I[O5*7-P;D0B57@9AQ<\ M;09H.'8$'"N#+4'(X9_!HQ`??XSXJ!'ND$=:&)"E23FHRSB5Z>.M&$F=)CQ. MK_FDF=*;?YS=_GC&KJY_ONS?75U_QZXO?^GOP.?SML%3![&"[ARH2'AT%8?B MX7OQV(BO`UIQ`+N^_]8'7X&0PS_/D@27*'7`HW\+GJS"_%:KTVOUC@S\11"J M2U"3B8K[J0H^]\%`"/U3EJ*6H/EB62P-)O-HJX3]J@MX>X=;+!2!G,#^P%?7 M'[>^/>C0?Z55-B"IT(/V,#D'.D_`,*<^A6?4KLQ=`-P9B.?Q_UD+W M9A-\:\#?G7,]/HM#_.?RMTS.>`13]%EZSI/D$3;L9QYEHA#S3_V+.1DWKK$B MX_O='ABX)V'9.%V]WM$<7<>D>.O3=::U2/6S&6+`/!WR\B7500X"!6JB;_@C M'T3"ZN0::^B^W3OJ>:AJX3X?==TB#\J+7([Y(A-WZE9$8-G"&P[&1^CU%[[7 M/>H=%N@7P]X,"74,Z'9*'%B1A!\D'\A(XN-U9/:XUSDJ<'K`UD12N[#RUBY" M<@-!G8`%AN0DUS5+'J(:@,]$6+>Z)R#T8H!UEU=F917@<[`MU\E&;&=A"%NJ M8G!$7(97\3F?RI1':RRQ5;$$]8`W@+QNQ6L@OQ4II)0BO.1)#!Y%@^G*)AGI M[848RD"N8X]:^P>=H[<%(E9-X@[-K+HC#R)FK)]!*?V4X+I@@C)G$``2YF1 M1Y,.W9;3=)"98(U M>7*PE`H#?3,4+(KKGD_!4\ID:S*B6B3;#"WKL601+;=B)N*L,3.J5'`:4@@' M;!T,>R^.H?=T#$,9`2MCG458'?PHGL,G$YO/0UP/40.[-HNH@6N-B!P_OQ.Q M2'@$\=59.)$QU>)3.1.7#U,1ZZ:\;@D_NWM^8+D$S09):N!\[Z"S]R5(:MBC MO;5)NDG44&A-^>/S)+_[]NUQSX^%RH"?@[5A,_:Z!T?[+X.UB=^'JV/]:2J0 M_?'(LO\9+.[M=[O>/L]!?A;>)B8?ES+:S>)M8',EDV[&BYL@TQ^4?@:#6Q4. M%S#70]7`TU:%J<]%U<#&:D5B`2I7)'%1]P>N90!&Y$)&6>J'<0LC_F4Q1-L/ M7I:@>P'2FG8#:.M^2=I6"UM6H0L]]2]"CL;PQ=D,-&8DYH+#A336A:,K1#QY MB/!$Q"]'\)+(Z?41W"P`ZY+J!.=:I%=QH"9BLT:K!'9MA$\P78L1PM>)X%I< M"//O55PYGUM_U=U>Z<1Q*::-TM7`G,I)Z-/H`D[BB3/X@ID,1?CA\9,6X56< M^]BS`$+&9<=IR\2E=_BV[L)4F%\($2H/R9JXAV,/EZ( M0=-QQK*,HWSRVX1D4]0T!;]K4K.`I1]ES.-@0Q)7X=3J*%^&TM6YN":E];TC MIL^F:@^>HH*?ITRGCY%X_\UOF4I/?CR[_>[J^EU'QHS^ MGZ;F>S=ZX/X8`AH6\7AD)UY>MZZNB['=-C.T,35D'G406K)SF"KC#'NR\>F' M3,M8:(U0=Q&L0[&[*K+YF5/\BSU]>%#PPGT:$8,O]: MS'C(F8K91S%(,IX\LNX.PW[N-KN#@18FD[!U[$+,1*2FV(")$$;YXQT&>$(Q MQ-X(-GADULWPB-F0$0GO8U[!DU"S#PK^86\*RC^>]3_X9-?..E>A',J`!,F? M?-8_]^<>=P]V:!LDLF^>9&J"!;_7IEV3?WCYR5>0K4C$=\IT38/Z)?$\'3F8 M@C=_&/5;`08(-00#PUQ`-6H"BH=F8SX3;"!$S*:)F$(V'*)><#8BA@6&86P` M:3$HX/U8!F.&5S0P;$O'/"7%TZ'5U%B!^B.H+-&DL0-K+MOL3./GLVR4Z93M6;7=*9$Q!KV, M50K8`S6*Z1P9OT[,<=4.D8!C.*RSZ&4B5<:&*0#_]?[!#J3,QAK8!1D5A(<^ M*H12895$HS`5<4C=H5-E5N2X$OJ[D$VQF9X-(>@G3DQX#,J*^V*()+81;QZ1 MFQ)!RN$C&V;D9,S])M)R19#0]R(7<:X:8->6X:8(@'5HY4+,653"A&D*&KK` MV*`;T9$'&:`I534["W1XHAU-Q6AB'DH=#U*5:)9P"9]T-L!2 M2XKK#U4VP%T:@:5#I`L@>QS(96N>[VU6*$J#N(>*1`/<0Y2%@N2"A[]FAHT: M<2`5*#E8(+*8D3E!!`);NC MQRJ+PI)\#3`XIFUH7GW)-'@)T5RD5&Z;DZ`>2&6<%L[G1D6@!D+?03SU(5+! MYU<27/7:K)]-)L@HX*='NN\X'?%_TK#J[O)?=P#DXO+Z[EVGW3N0\0E[)AE\ MFV'-DZSJ#:06H`8D*:^:#\]$B5:]UCI4K'N-;Y3D,T#O*9"_E^F8/EOQFR9@ M6.0T`B4WQC2*'O&YF'IAZ">PTO")HE'MQW2?^NR[L[,;/ZY#8X*-8N(!*``S M0T`^M?MM,&11Q!-=,7NUEIFN#;%'P<'PHU?11=C;.VJ_ZHU^`8$?;#/*HN7$ MB]C[N0R\:G8\7^XUA@UF]>!8LI!$<=7`<./"/X18Q)%3$"'C(<9_:(4HB'B< M\]H09EI5]<:2L@R52F$HP$XPR$E,:E9#3SWA2%"@\`IR6F\BB*!$P#A!0>>B M.,/Z\@'&$IQ6#U[TURP.B%)BW:)PIVE3<(EF>2F2`4$!4HR0IE2,0P6'N9Y^ MV[SV3R[6]=RR\@+1/O`*A9=:;BV#3]A8W4-*D-`^FONW&#&C<-G\`R*\+$E0 M1$!:@*&1V8!2P`BQW(X3;H4WU4V\5PKE$S_*@SV;&C\+H;%,0"871=3YDJ9* M2R/AZ7SF@Q29F!7[RLB'8=Z@RN6G@.LQ&T;J7N<2DXX3(>BAE@]L`LL?6RG2 M5HPJN$PZY.'Q4X,Z,:S,-XP`/7;,D+!X&8<4)L^$4VF'`!@U(,\G`M('P&"3 MC-]`ME.\7VR1#K/(^+?7+>8OX,R";?;)9,B7.I43-*JOF@4;T'3CC?+$:H'B MHSJC9\#TC:RM#:Z<6_"3;92T"?\,LN9X:-1)-*1L?#D$4K8QBOHUN MQ&9]0(E7X/"S/5?PB)2VE6&3QXT0\Z(Y!DMHZY7I(@-7Z/X\.8EK]<5!PK61 MA5GB4NTD?YF`4=IR[1/2\@P"3-!0,>-11EQ9S)_$G%FZ_#FT5SBH##L!4\,? M;)9L8)$MB\`:82"ARXCQ+2>:3-AB=#`]L/=OL;R@=]A8ZE0E$@-=7&LB!88H M.&\&=D9E,`<]9EZ-H`V5F(!'$ACEK$U";P>P'06A,.8ED$F0308+*^6>&F1HKRQ M'(U!<",)C$!3I=,D,YIJ4AN423"7Z:.QP1@M491$<0=D"[F=!L$D.RW!1%%J M9(Q)E8N9[VUQ&+R31#RQ(##R+'`TT\ MJ,EYS_KGK'?8\0[<7$MIP;OB+*GMQA>AQ]2KL]'I!AAG+P%QB8B':O0&$H5PU)2B7R8NHNI=E@Q7PY;=B`\-+/;["JV'";LQ5), M`.$X9$!-(7(1U1P*MBBS%;]0@'/$6R@6X1Q?*3@R\1<8GBDX^3''N;E3%@\B M":1)%0Q.Y6*IA-U#.,+)0/DL%P^4/>M%O+:H)0F;3-SFX*$Y#,AGM%^W&7D! M\SK<]BJ+5X5;>=5\>&['1I:@[R/=1'MWU//MXT<.\F%ZO7XD5?/REXL\-]*L ML)KXQ,#Q&QL6LY4>8S&$"7K?%XIA7@&D_.Y!3O`H&I4A,WJ@!EHD,[)Q,@9% M-?2@FE5'9O'\V/LQ!*836@VJ)=9R3#C?=@S`D!5F2#U&)?)&0.0!V@\Z:K*= MT!GO"/LV*)"(\R/D'2#S5Q&0[@EL:T0W!#@32/3R4U-+$ID+7*SA<9FF4H'5 M,<\/T@/SZCCY.\]KE-(YE1K*@<&&^/R,&_(Y6+&_BBGE.YR,@O9.[&R:Z,&= M%&)1\`_,(M"3PF9H?YDRIOD8CQ$N=Z+*S7GI0B:\>]4*N(XA6K59Y0?:DNX\ M,7^\;I?-H[3,P7S9M+4HEXQCF._EXNB?3;9?I*T(!>2-'+@VP2*IZH0GGQ$$ MG7!0WP:6)FKA_ODRT:>)9>\_8MG`G/7$TEI*4_0!ZQA7!#4O&'E^S86?IE#G M(8&X.`/H7%>`X`0-OC+BR0+2YO3AI`;$$O5`($Z;*/T"[Y4-L54+"T@S%668 M?.,YXA`=/E65()K5/##Q[1N3J9?(V#[!&1,5BJ@%R0P\"8O*)&$T#/5]E@L1 MRDS#\T+@[@!KG@:./4VD"AF&WSLT1H'#'MAVU,'CC@_"T(3%7OY7-P5[_S$% M#Y8E+]":Y? M7*0B),3)OJ'`LC[78W.:ZPYQ0M=$:\Y6IN;EH'X5L3;KFM\4E26F&$F]J::4 M@';(Y1Y%4'2_0!^L>\>H5G=9ADU+_$[M6;7K:ZAQ[SK"?0>!D M,HK+&6GE&[02=VHJ`W9T<+#MC$3%2;,! MA;LM7?$J$>8=]K3GB,Z/EHH"J*N[P3?]RW-00/P!":#-M7/050R[/#&SS6R) MRD;CHO8:!HF&EX7U2O=[*B^(+%X^<>>540K+]=KN!>VUF26: M$=7,)WN>17^\>T"K!*^ZMC78%V\\FV%?P[.CWB%[,QD?6$!*`-/\IN&F-FB M]143^%1:MO]VT94EL7RI+3?YQFF_-GG=QWMLE<#BSR"FFT?YBS"VLL&=SXB>*'U@!!`?1TURYQ;KGNI]2^Q#K-CR*F9@40...[@]QW M3UK!%]NIT@KL'JRW`GPW]I=?@?D-OZ>OH/(&F]>@-'LOJ#255^>\AN7V7M9& MT%N?OKQ\=I^@8?CV!2(?WWQDQMKCDF_M#Z6^@R>GN^Y+`H"3RK/MNRW+`$RO MW=*Y_MM1#0!J['2[@^.N7=>F^6XYC5]93)6)!.RBZ."L@JNAV$&JSCK=+:C, M5W5*OQ@+?_P?4$L#!!0````(`.%N8C^;=M<::@(``)0/```5`!P`<&EN:2TR M,#$Q,#@S,5]C86PN>&UL550)``/U@[%.]8.Q3G5X"P`!!"4.```$.0$``,57 M76_:,!1];J7^AXP]\&1"2BL55%9M_9`J=0,UF[2WR3@WY&J.S6RG@?[ZV2DI M'QT=91EY(;)S?OR/$^P+RDE.5:8]X>(,6LZ4KPEU=@_;K<[?EG8.#H\."B*>U.-*POR3ED>^-\_ MWX4L@902%-I0P>8+-?9T,7\G&36NK[]3>ALKW(B49<1-D>"8=(+65$=+0F/D M*S23A*J4HG@`;:R7`G+=8C*UF$'0/NL$2TL=^!M=>;%D[DO0[7;]XNURM86+ MS'/Y,OJI__1RK1I?D?/LME>K5T'V M[^DJ?TWF#:FR<29@T+)68^4:9,W&KJG9G\VAH0;<7M&#>#`!51#M[/`&M/V; MNT%(/;Y>4IW<<)E78NL"K%Y7%SKV9^H5:L:ESA0,U)@*?"R8+FVRDF-4#.R1 M/U2@K<9B.(AO4-AMAI0OQ.]\ZU5$7\/%6)'R.J(.LS2E:C:(0QP+C.T!:2]V MQF0F',30-L`0*LAT2YXZP]M28ATIW8-E@8V;V55&A*?NGFV0+Y#J3V"BJ MGATRTO`KLSOT^J&:\^T%8KW_^C4QKWH\?U%^Y=F9WU!+`P04````"`#A;F(_ M0EQ7/`P%``!<-```%0`<`'!I;FDM,C`Q,3`X,S%?9&5F+GAM;%54"0`#]8.Q M3O6#L4YU>`L``00E#@``!#D!``#M6]]OXC@0?NY*^S_DN@]Y"H'2GEJTW(KM MMJ=*O0.5O1]O*Y-,P%K'YFP'Z/[U9Z<)!$(@1U.2G'BAQ(QGOIEO9A(/]..G MA4^,&7"!&>V:K4;3-(`ZS,5TW#6Q8-;U]=6-U3(__?+^W<>?+,OX'=@M03P0 MAF7@>TS`&`980JS#:#*DP?C8OF@VVW8L>/[^W=E9*-Q9"+RV8=Z.Q5OVW[\]#IT)^,C"5$A$G6BC MP!T1KC\R!TGMUWZ31J:$OK)B,4LO6:T+J]UJ+(2;`.IALF9F.D'<1YC.0$@5 M2PIST7"8KW2V6LWK=BNQ52O_CU%);8GBTKJYN;'#3Y/22ITKE^))[5?VRX<; MTG@'G&6L%;]G+P0C[G!&X`D\(WK[Q]-#VAZFTG:Q;T)END3>!NZ+Z@+0AHHL'_P1\"*AKNE-X(Q!;B+,TU7L$#)V M^;$$0(I#`[VNY.@173>OK4?F"7.2 M-DVB;[2,FTF7S&1A>4B,PE((A#5&:!H:LX%($:^$SEO-5G1G_1`M?QM*)$'3 M^16-",06"!H!Z9H90G;)4!4G\*#>BGUP5X))R"MR>WP=O.I)L/7WL#Q!68"4CL(%),)6ZH++L[-;]>`UAYT7M.*\H9AO>W$'4L?;2O!7XA2]`(Y M81S_`#<7;ZE-M>,K[?9VGB[*X^F6^3ZCAQ19GITU8"Q7`+;3UJX$;3EK:]>. M>M&4MZHN*T3/@Q!!?FHBZ3K2$CNZG9*K"E'2#Z2>ZNFI;UY>DEOJ2,Z:R]L9 M^GF#H=/![)4'LR5FT??Z4^#A3.;@,UF&MJ,?QS)PG$YB_[^3V`-5*0!+/+V1 MD!PY,@-WEG1)X)]@!C2`K"@O/RZUF^^)<+(#KORIW(DO:@-T?+>8`A7J"6UW MIF3+UX6,'1X7>,Y+WP@\3-2]G8J`:./WD$KO+0*EQG1O:NBH;O.JK[=E6?G-S^5V[`,>#,`R%"/%M*)5.L/IRD/:S< MN"+E3]Y[0HUHV.)CY>82.E6P?&1B5QE$`G6Y"R=]JESBWR%.54J(>)3X&0GL MJ.[Y!9-`9@Z$]NVJ"S5[O2^P0+8_)OT%>#Q1IGHS59QC2(U!=O-QB(:J\>4T0=C,@J^0_^W6%!YH__T\2"@)=` M]##P?<2?^]X0CRGVL(/4K=1Q6$"UBH'"[V`H@-&<=DJD+B?"$CAZ`J*_IQ\@ M+I^_LQYS1Z<+=<4.```(KP``%0`<`'!I;FDM,C`Q M,3`X,S%?;&%B+GAM;%54"0`#]8.Q3O6#L4YU>`L``00E#@``!#D!``#=7>UO MX[89_]P"_1^XZ[!L0!W'O;NAR>Y:Y/*R&RV&X;AP$BT39PLN:24EP[[ MWT=2DB-+XHM,6F;VH;U$(9_GX<.?*/)YX[L?'I<1N$>$XB1^?S`Z/#H`*`Z2 M$,?S]P>8)H/OOGM[/!@=_/#]5U^^^]U@`#ZBY"R")*-@`/`ECA"89#A%)0WP M^O#-F]=OP&#`.T0X_GS"_W<'*0*,54S?OUJDZ>ID.'QX>#A\O"/184+FPV^/ MCEX/RX:OOOKRBR]$XY-'BCE9PFD+?AO@[+9@#\:C+X=O!X=/M*P(N@,1QML5@M(EA#']XBF3)J"'0;)D-$>CH^]>CRI=.?&.6FET*?0R.CX^'HJ_5ELSN:S>\7[T@2H5LT`X+G2?JT0N]?4;Q<1>A5\6Q!T*R=7$3(D/Y9ZDD*26HA=Z5_;Y)/V6*#MI*YTK,_:9,41MM)^]PSES9?4/F#*_;3AM#H M,45QB,)2;$Y'\1X+-F*EX(1+RDE0I7D0\14T(0=531Q4UY$9I'>"9D8'S1IQ7&"G#3Z[,?_W9]=7YQ._D#7"7T+^#\XG)\-IYZ!SFM'AHH,YR5KL"B M*#B<)_?#$.$<4^R'.I38HT\7<>(;94)K,RUOMS5PM*QM\)(3 M!FO*("?M"UBT8R\Q8JCW_M:XQ^X)_>/J)HG`<7^*8[;39Z>$T M2/$]3C&J(V@+`M9K4G=A;3#'N`'.#I3\P!W'7<$+/#/S!87;JZF^A&T[J?WA M=AP'!+&CZ3G*_QW'URM$(#_PGL$59A]XS;>S`P%KW'87U@:W9POV&Z(`QR`I MV0!(*4HI@'$((@SO<"1F[\0WZ';75!VZV\YK?]!E;]4,46ZQ@M$EDBZLC6;6 M,)0QM@%;E2:8(?\60]F@Z[A1J[L_=%P]OYVG<=C<2TK0HNUFC1Y3P6S0)(P. MH,))+%A57N5A`?V`\S]`TN461,+E!PN4[RPAA!V@) M#!4=K`&H%\8&>HPZ2!-`$CHC<0A^P`(M^WUQNZ MV)]+F-L`):<*4OC(5A,<^H(0_:!;MM1*E>_=6K'>X6]KK6@CL"MKA4)8)]8* MS@6,8[#F\_(L%0H5&5HJM!/:'V;_BF(F2\3V=:?A$L=BK64RH8O'%8II'4"F MO:S1:2B6#20+%F(/#S>8^(9#0V74P==IDOI#W!K\A1Q48PJ3M[=&F584&WP] MKW`E=?"?T7]5V-J+^.G:[V\T!M_>#:T.ZF^%(9SZ>Q_.DN4RB<6IFIV`KLDD MY8>AGV&4H1M$)@M(9*NP24_K=Z2#>%9F8<$&4,[G&WZ^94ABOXG3[CUGYAOP M.NBE#L'.\]8?&$^%(5ZS(M<:64.LG:D-FDXGDXOIQ#?(M(^SC@Z5=G=E!CE/ M@HP'GJP#[LX9(EOL(.WMK`PA2M96)K.",,@I`T8:<-J^H$([^*HQQ$#Q/>[@ MR!S&^#<1E726Q#2)<)B'*,7A#9MN'L'$?[V>%2Y9&(DEC@]`N]MS0MM^9^AR MB%8'9YAF!(%D5IZ8F3#BR,*D8KN8C$<<\[]^R"B.$?5O?^92D8V]G'NP]+CO M@W3!Y.3_<#<*V^1PJ?(7O.XFEFT`NY"PWPEN(;"EA5+0`G\LJ?Z)1PUP_KZA M?!O5-':%6T]FC]O#,,2I<$)S4^LX+F(69/M$26O[#:-:#*N=XYJT,(L/&."" MG+IOF-,HH;&M-)F,7>TO"Y_>):8!C/Z)()%O,:5-K7:9.@&LCJXY;9`3!YRZ MEYM-G0ZJ^TVS6=@57$[9!SKD'^G+",Y;,++Y=RM@M+*R6D!*@H!3]&G^6X=: MG72%6DUF>H7C?#9Y&I^8RQF./OV"\'R1HO#TGFU?YTA8-^AUEO)D.9Y,^0%2 M'+#OWCF.,M:L-DW;4-@:#Q;BVB"F9`D*GB!G"BI\8C# MXM0J-N$M(Y\N$(#%H.-L>8<(/\K0?/@)`5F,4PHPI1G3#A]Z4E%)NH`I8"U! MQEV*XCL=!5F4FZOOUMH*<['!QWT4+MY?MJ_6+TMVF\1?%=48V+V5)RQ?(R,98W^:U:W.WX5/%9N$6K1+"WSY^QL[D.3V2Y@["J=2" M.`BK*K=Z:PX@9^$+2DQ5T8RS,IF4/G-@[RCZ-6,"7=SS4_`4/:8?&+_/DC5$ MWMY!GJM&%+O,UI(XR*F[=A$[D5[I(FX,P9=WP5@%S3Q<(S#U:'4)@B3CUM[Y M31+A`&M#)A0=[&TO6F'L7HCEDB=0LFW@!,]C/,,!CV%]9@I*KK[!3*^7AD7& M<);V'L#8DEBG`>`6A'I,OW0)V/^OC$L=9&WG=2^)2A*,5ENX3#]R@:I&II%O MD&H9KR)K:+_1++*/9/Y'1]$K[F8]I^?;A&^.LCUFQ2]/ZBE;J@AY8JN2B*SJ MY$*M]]V1[U0BHI4S@@?9.SY$.!=>>:#0^7?W+OVJ5MU+-@L#\`'-<1SSS0'; MS^:>W!FGQ7RUO MY\*:UL[:A1DMIPP$:!;#&^SXDAQO*0W\`G>1;+OG[[?#NJ+ M2$2SS1XM67K;F3U4A'K, MX]Q-,NO:R(,(%K%K[!R4`;BJ0R]>ST64H,S1`A*.R" M,DTG!V7&3(2RP=J:0UX:Z@7`S4PGS9IDYC/59YGB(L'C"L=HS'Z4?0);&CHH M2RQC;N44+:F"?W&Z0!#^MV\@DH^]68)8K?D^0]-2R&0(+R#A9CK*#B39,A/5 MJ(H:;A+P&'1T$,YF*ISEP;FD"L*<+`@SDD=8(O;H'D7)2J"/IG#NW7'47$O- M4+EN<]CK@32O:G254$6MH$H;%\?()DO;BC\1HP5F"1%(6GEI+6X==\OY3Z;K M?=;?EW[8W)?7W&5!S9=30-.\9*8_13(KYP*E'[3>S.6)SIUW,S_&":+@>:]Y M`KX]/OKFZ$C\!X+BK)?ONA]PN@!05!01=42XX^KW1X='1R.^(N6MP+@UQ>`$ MO&TGZALN9:I6G!%[=&25M0N>D\DNV9.V^'!92R<%)B3LG928J*;^">J^(,1` M`6UE)I03L'TN6$G^-`YSYYG^7B/C;E997UT$XEE+=)T-'Y(10>7D:X285SD MTK^,T%>)`A21L,KIZ/62CP"AD%ZRD56JKS^=HSL9II1=7%S^H17(SB:?TP=\ M+C?*Z'L3>]1%%2W7@QA.3G\8*\UJ94E#=:*_:2]KI!F*96OZXI8B<<`43+KF M[^\#=X:*J4.OTX3MP0TT502_U1JY<_],786U55P_@J:_7I^I*O1+I>A]^:-5 MUK"VEHX]S\YL8C5W\X99;/1L%5NMF[DPC,4X:E#T#9H*?:M=V;T'>8M+-L_8 M*S)/B#S$>[.5@P#O5K8.PKL%75`2]@46FG$W([L5^MY?)03M]=^2YL[K(+C- M^GYA-03T5WF;3$./#F511?9Z]EQ#5N95;C:T=RU+F5MMLCL6QG6=$&`W*F4& MP$NO^2M73<.QKH';/KWK'T5!LNM9'MC&CM-B6\!.-M?I`I%S3(,HH1G1)@6X MH+P#__W6P[,[SEB+X1O8'6I6'T1@B9S]W!-K;*O>B9':)7ROQJ>Z[QKH]:#U_+PI@8JLM?OD@TTQ7$6LK"/!\XJ6OD%(HP5MPD'; M;/034Y(GHIM%E53;.HPK:1'!961)<8>)Y[$E+4J01Y=()V+'"?5UV%8*IDI- M+\I.+E+M#81RD7>_L1@URPS[A"QSQ;3DY!M/5Z\NUQE.%0'=E08NW*DU9B[\ M6;[`0S[*%K]HJTYWN\3\@J+HQSAYB"<(TB1&H?@R$NGJ(FOO8&'1B.)@3>$< M!I\Y"U#RR+T&Q!>X&&NCN9`8SEY>DE] M<[#-JB[BZB>XNK-X_ASKKA'H0L%!>G=G M<7>S\W+M&=W1P)0N4__WE1;::2:N;PG3'MVIS\7[FV7NM;=YF'6V=XIV$M(N MP,7T6@/G%X`X'Z/F-I"7>G]#-T4U7+5;0';7OI$I(ZMPAX@_._&`5!DY<7IP M@K[@0S;0-L=&4Z5[=*7*_1I&7=P[51W[-%H]JXE_SHPN^M#Z6#UP9-2*MA89 M;1*(21J[NH5((H1E/22OR^^J1RZY8ZA5_]617;&?V+/R$?O?':2(/?D?4$L# M!!0````(`.%N8C]\7`K!>`D``"R#```5`!P`<&EN:2TR,#$Q,#@S,5]P&UL550)``/U@[%.]8.Q3G5X"P`!!"4.```$.0$``.U=6U,CMQ)^WE3E/_B0 M!S\9XX7-6:@E*2^7%!7.XL(D.7FBY)FVK5I9XT@:P/GUD68\,#?-Q3=IG'W! M,.Z6NOOK;DDM:?CT\\N,M)Z`<>S1\W;O\*C=`NIX+J:3\S;F7N?CQP^GG5[[ MYY^^_^[3?SJ=UA?P+@AB/F]U6O@:$V@-?2P@:J-U?'ARFW3?'QT==R/"@^^_>_Z___?[="9P@QU,.4"46?)R/$9#Y[?>@X22J_R+EM:"O57)R+KJ$>= MWOO.<>_PA;LQ0<>8)+J93Q&;(4R?@`MI2PK/_-#Q9K+-7N_HXW$OQJH:KVF5 M#,O2+KW3T]-N\&V<6C;GBE?R>.L?NN&7*6I<(,ZKK26^[T*`F4?@'L8M]?G; M_4TM.W054Q>[[/'2<_P94!%]]JE[1046BQLZ]F0;"LF#5J#BQA5&/U1NN_NFT9P!EV3!\UOY(-$MO`B@+KA1QTJ#;>JL MQ%K*13PG+DJ;*`_W6#MN@G;6!-(Y'XNZZ(^X8,@143L$C8"N*&'=% M#L[AQ'OJNH`#"ZE?`O$[1[UEG/T@'SV&W=_#!*M>J?B"9I`26$L6%S".;9\E MA47,B9J4OP;`MK61L*3HSA&3[76<*29NQ#UFWJR&`2,AO`(=6CZ7TGASQ8A( MN^4Q%UB8LG=B_TB1!]ELCMT37S?,WDG5\NW\?M=V'@##GM3!O42BR.!)NH9: M/J5L/@3'NX*@+T5RE5C7!$UR3)_\OF$F3RF7;^J379DZ%/M"BL,0N9'#ZLNO ML-"F]31=PTRO438?@@^[@N#"9TK1:\P=1/X$Q/0Y1TO:,"#T*N=C\>..P\&; MS3PZ%)[S=2CGDL#O?*%FW6I5IH^-(J:&X5/%#/E(_7>W2*D%,+N0GC/QF#YM M):D:B45*T7SC?]QQF(11?`]SCZF%UE#:T>?Z`,DG;R0<.M7S<3G=+2Z_>\27 M1F2AT^@!2=,U$HF,LIIEVM%N,?@#"/F5>L]T"(A[%-P;SGU@6BQT](W$1*N\ M!IN=KZ'?)A[7\DE>A.@H&X:'5F$-$CM?98>"A!9_B\,T%H'OHT$,&C M)VGG7CY^[',N.]=4=C5$:T7>ZJ)>(#Z5;JP^KO[R\1,B$B3>%Q>(L86T].^( M^.G5:#U>0W%:C(6*RIHFT)>`6U*M,/5K7N+T0@3+#"4I8`\2NOMGJO>EHK&&P%AN5ZKCD6:P3`D!?ZD MP26C\9:VK];(0([CR:4;'Z`%&A%8"JS+2/G$S8!%IZEU:>O2AP?O'@@2X`X0 MB_F1!I8"AF9`4Z2QS0FM/(,U!("$3EO:#%O=XD'Q>^H1*0=7$T.Q*!E""ABL M']6+E+4.F4$TWPZD+EJBY%$:QJ+*XY*IJW7`>VRTJ7#"FR1H%159)Z\;P MONOB4)H!PNX-O4!S+)1H^?,J#;7UR4JKYI9V\U<'Y!X$PA3<*\0HIA,N9X/^ MS`]F')_F?H)=2OC4BMSTHW\5;>.RB$T/D_)LW(RL+/* MEPJ#0)5IR"P@\AF]IA239K><4J)8\L8]L6?C8#=C<.S7%+(8`8KL\R= ME)5=8NX0C_NLM&*]B99-Q_^*J!6UI#:CHS:V]?4$U->>5GG]VK"KE-@XN9\5:62=IRSS M&IU7+" M14O6)%2R.EI7Z,CH4W54:100.5I:5]%0SH+%K<>+0F%)T)R1/*Z5=.S*&7F/A"6TPJXVH..*7Z;S!(\J=,?P">3&57_2<9H!/(%%"*$5FE M!?O16GRFGC/&RDSO35FN,KT)HB9E/4%A!)!IM4G++7[O/B- M@WM#7P>XOB.G?54N**[0D*$L+24-HZ9@;$S2&([QU3&*)^>4VM8MNJ1P#!"' M2P@_8PHN#VV7%[6J-K`7@-8QF'7+M:SPJ=N/E4%.\YD?D&NZ<3&F&;/LT8(NIL8(I1U-!>)/I5#&C=VEA*[P"X_%H:*':1 M>G$)(QW>A2QV(EO!J5/5C`*C6#=%JZ[TVA&\'_C6,9AU>3O_94?AZ\C2PYGN M-$Z=)O8"\7I&LRY+[_T[OC8S(J_U'K"3^E/U>>`_0R''!J,3]JV[QV/O7^0@ M4MF".NM*+G)%7:,.,O3GN$AE4UEW[_V&"I!6%^J- M"MHR38S$]`F_>CZ9+,?$-;5N/A[6MGN(K]&$UE%64T^@[> MF"!E;ZS7,YB:Y129]4%"^EEV_E4W\ZG&;/JU4:4H)69&%0VR/^DFOL/RP!#E MTC+KW%NLT++1E**5:C-G+1,;5J6O!:K"8>SZ6;Z=WD0LRP]U6C#XSV@J(I:\ MR%;#-ON3*H;^B,-?ONSLZFDSJZQ,BX9G&REI3)6+DV*4UHX[`$ M``!W&P``$0`<`'!I;FDM,C`Q,3`X,S$N>'-D550)``/U@[%.]8.Q3G5X"P`! M!"4.```$.0$``.U9W6_C-@Q_O@'['[2\^&6.XZ8]M$720Z^]'@IT3='-W M>PX!$G085JZIZ<:I235S";A@',DZ9@1*# M]+O'Q_UCXKJ6003694Q92)9]`&M1,PU]U`QAEG[]3R46,4FZ0&;J2*KR&B M*3=#)Q5?4\I9Q"!$VSC$(,P206W;4#4%3>PFI^7ZC]"1#*SS\UK`L..9G'"H5.LS11$PPXR,[<\\J=$01?U*DF4 MY,BVU6R[[2&+QAN0:717"2XAJ`K64-;<@B`R`648Z,79=[RW,2F$:%^3D`4A M?E2#.)WL:Q"R`/\1;0DHW]<69`E2_IVOF\7X@C80._C]\78);U?BRO5DH7KZ M2+E-"^,9@-$/5&&^OZ M2A!.ZK)^)4O2"!4AJ&17LARG<4S5ZR@:LZG`QWY`A;D, M`ID*"_&`R2?`ZKHI*[;D;$Q__FKZ*T"M%VNPI,(E)?#!M5M<*X/41D+Y'VO4 M)SPY\WJ+'Q>(896KN;,-=9,+_:R"%=SUH2U6.12I81V\MCM%CO!)FVFS)4?6 M]IL\<]R<)"N4@T]V)X>?VBJ-`T6/%/"]K&1'BTF@@+&)+AD#K0 MP5V[:]I$P]<43?_TO.U-OT;3Z)[^>ITJV4G.___QRL"K=:)PLM2F&K`XD(C0W%+3TY;U\%0J,\V\#P!)8D MQ0(K_LR*]]^W$K_*_RT:2''_K4I(X?YK16H-2ZO`R3;1&SN<;:1EC!M[GAYP MH\L5M^J";E.AJ7%*6JNRVD*W@Q;"&]OON?"B4TX$XYQ../(:E=J.L>TMGV-5 M93*TP31TPC2OL`[)VFA.3J&-PD1VBZ784CF$3G`%:Z.V,7*2?]6CA3!AIKWIL11@\.ME MW7C;QTFY+6`W`+I4?G5UA\7_[?6KOV.JTJ?WO'D[4:Q1`R^/9!S^`U!+`0(> M`Q0````(`.%N8C_NQ<,+714``'5X```1`!@```````$```"D@0````!P:6YI M+3(P,3$P.#,Q+GAM;%54!0`#]8.Q3G5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`.%N8C^;=M<::@(``)0/```5`!@```````$```"D@:@5``!P:6YI+3(P M,3$P.#,Q7V-A;"YX;6Q55`4``_6#L4YU>`L``00E#@``!#D!``!02P$"'@,4 M````"`#A;F(_0EQ7/`P%``!<-```%0`8```````!````I(%A&```<&EN:2TR M,#$Q,#@S,5]D968N>&UL550%``/U@[%.=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`X6YB/WNG"W7%#@``"*\``!4`&````````0```*2!O!T``'!I;FDM M,C`Q,3`X,S%?;&%B+GAM;%54!0`#]8.Q3G5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`.%N8C]\7`K!>`D``"R#```5`!@```````$```"D@=`L``!P:6YI M+3(P,3$P.#,Q7W!R92YX;6Q55`4``_6#L4YU>`L``00E#@``!#D!``!02P$" M'@,4````"`#A;F(_:&5>X[`$``!W&P``$0`8```````!````I(&7-@``<&EN M:2TR,#$Q,#@S,2YX`L``00E#@``!#D!``!02P4&```` /``8`!@`:`@``DCL````` ` end